|
NNT expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.53269996694405E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.53380033305484E-10 |
| Normal-vs-Stage2 |
8.521800E-01 |
| Normal-vs-Stage3 |
2.44369999791161E-08 |
| Normal-vs-Stage4 |
2.22832863272515E-12 |
| Stage1-vs-Stage2 |
9.296200E-03 |
| Stage1-vs-Stage3 |
3.962400E-01 |
| Stage1-vs-Stage4 |
5.744000E-03 |
| Stage2-vs-Stage3 |
5.120500E-03 |
| Stage2-vs-Stage4 |
5.773400E-04 |
| Stage3-vs-Stage4 |
1.617010E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.37172520406648E-12 |
| Normal-vs-AfricanAmerican |
3.57189999999896E-05 |
| Normal-vs-Asian |
1.141080E-03 |
| Caucasian-vs-AfricanAmerican |
6.450200E-01 |
| Caucasian-vs-Asian |
5.930800E-01 |
| AfricanAmerican-vs-Asian |
9.340400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.69739999944518E-07 |
| Normal-vs-Female |
6.17539996916605E-09 |
| Male-vs-Female |
7.515600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.49009999894645E-08 |
| Normal-vs-Age(41-60Yrs) |
2.16679996167812E-09 |
| Normal-vs-Age(61-80Yrs) |
5.842600E-03 |
| Normal-vs-Age(81-100Yrs) |
6.834800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.002000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.378550E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.652200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.938000E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.732600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.973600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.376200E-03 |
| Classical-VS-Follicular |
2.42359999998998E-05 |
| Classical-VS-Other |
8.980800E-01 |
| Classical-VS-Normal |
1.16670006988784E-11 |
| Tall-VS-Follicular |
1.19169999979185E-07 |
| Tall-VS-Other |
2.301600E-01 |
| Tall-VS-Normal |
6.55031584528842E-14 |
| Follicular-VS-Other |
2.538600E-03 |
| Follicular-VS-Normal |
9.728000E-01 |
| Other-VS-Normal |
1.282360E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.07369999996698E-06 |
| Normal-vs-N1 |
3.9922509742496E-12 |
| N0-vs-N1 |
1.179930E-03 |
|
|
